IP Library › Granted Patent US 12,521,410
Granted Patent B2
US 12,521,410 · App. 18/493,421 · Granted Jan 13, 2026

Compounds and pharmaceutical uses thereof

Inventors: Guochuan Emil Tsai (Pasadena, CA); Yi-Wen Mao (New Taipei, TW); Lu-Ping Lu (New Taipei, TW); Wei-Hua Chang (New Taipei, TW); Han-Yi Hsieh (New Taipei, TW); Jhe Wei Hu (New Taipei, TW); Tsai-Miao Shih (New Taipei, TW); ChanHui Huang (New Taipei, TW)
Assignee: SYNEURX INTERNATIONAL (TAIWAN) CORP.
A61K31/7048A23L33/10A23L33/40A61K31/235A61K31/36A61K31/40A61K31/415A61K31/7034A61P25/18C07C69/90C07D207/34C07D231/14C07D317/68C07H15/22C07H15/26A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,521,410
App. No.
18/493,421
Granted
Jan 13, 2026
Kind
B2
Abstract

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, in which Ring X is a 3 to 7 membered monocyclic ring, at least one of R 1 , R 2 , R 3 , and R 4 is OR 5 or CH 2 OR 5 and the other R 1 , R 2 , R 3 , and R 4 each independently are halogen, OH, OR 5 , CH 2 OR 5 , CO 2 H, OC═OR 6 , (C═O)R 6 , R 6 , C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, H, or absent. Also provided herein are therapeutic uses of the compound of Formula (I).

Claims (19)

1 . A compound of Formula (Ib),

or a pharmaceutically acceptable salt thereof,

wherein each of R 1 , R 2 , R 3 , and R 4 , independently, is of the formula

m being 1, 2, 3, 4, or 5; and

n being 1.

2 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each of R 1 , R 2 , R 3 , and R 4 is independently unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of C 1-10 alkyl, halogen, —C 1-10 perhaloalkyl, —CN, —NO 2 , —SH, —OH, —SR aa , —N(R bb ) 2 , and —OR aa , wherein each instance of R aa is independently C 1-10 alkyl, and each instance of R bb is independently hydrogen or C 1-10 alkyl.

3 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each of R 1 , R 2 , R 3 , and R 4 is unsubstituted.

4 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound has 8-24 galloyl moieties.

5 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each of R 1 , R 2 , R 3 , and R 4 , independently, is selected from the group consisting of:

6 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each of R 1 , R 2 , R 3 , and R 4 , independently, is selected from the group consisting of:

7 . The compound of claim 6 , wherein R 1 , R 2 , R 3 , and R 4 are the same.

8 . The compound of claim 1 , wherein the compound is α-Xyl-8G, α-Xyl-12G, α-Xyl-16G, α-Xyl-20G, or α-Xyl-24G, or a pharmaceutically acceptable salt thereof.

9 . The compound of claim 1 , wherein the compound is β-Xyl-8G, β-Xyl-12G, β-Xyl-16G, β-Xyl-20G, or β-Xyl-24G, or a pharmaceutically acceptable salt thereof.

10 . A composition, comprising one or more compounds of claim 1 , or pharmaceutically acceptable salts thereof, and a carrier.

11 . The composition of claim 8 , wherein the composition is a pharmaceutical composition, a nutraceutical composition, a health food, or a medical food.

12 . A method of inhibiting human D-amino acid oxidase (hDAAO) in a human subject having, suspected of having, or at risk for a central nervous system (CNS) disorder, comprising administering to the subject an effective amount of the composition of claim 10 , wherein the CNS disorder is selected from the group consisting of schizophrenia, psychotic disorders, Alzheimer's disease, frontotemporal dementia, vascular dementia, dementia with Lewy bodies, senile dementia, mild cognitive impairment, benign forgetfulness, closed head injury, autistic spectrum disorder, Asperger's disorder, fragile X syndrome, attention deficit hyperactivity disorders, attention deficit disorder, obsessive compulsive disorder, tic disorders, childhood learning disorders, premenstrual syndrome, depression, major depressive disorder, anhedonia, suicidal ideation and/or behaviors, bipolar disorder, anxiety disorders, panic disorder, post-traumatic stress disorder, chronic mild and unpredictable stress, eating disorders, addiction disorders, personality disorders, Parkinson's disorder, Huntington's disorder, multiple sclerosis, amyotrophic lateral sclerosis, ataxia, Friedreich's ataxia, Tourette's syndrome, nocturnal enuresis, non-epileptic seizures, blepharospasm, Duchenne muscular dystrophy, and stroke.

13 . A method of inhibiting human D-amino acid oxidase (hDAAO) in a human subject having, suspected of having, or at risk for a metabolic disorder, comprising administering to the subject an effective amount of the composition of claim 10 , wherein the metabolic disorder is selected from the group consisting of obesity, hyperlipidemia, hypercholesterolemia, hyperglycemia, hyperinsulinemia, insulin resistance, and diabetes.

14 . The method of claim 12 , wherein the composition is administered to the subject by oral administration, by injection, by topical administration, or by inhalation.

15 . The method of claim 12 , wherein the subject is administered the composition continuously or at a frequency of every five minutes to one time every three months.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2024
From: TSAI, GUOCHUAN EMIL; MAO, YI-WEN; LU, LU-PING; CHANG, WEI-HUA; HSIEH, HAN-YI; HU, JHE WEI; SHIH, TSAI-MIAO; HUANG, CHANHUI
To: SYNEURX INTERNATIONAL (TAIWAN) CORP.
Reel/Frame 066527/0701 →
Continuity (4)
Continuation 17699784 · Mar 21, 2022
Continuation PCTCN2021089301 · Apr 23, 2021
Provisional Application 63014448 · Apr 23, 2020
Related Publication 20240180945A1 · Jun 6, 2024
References Cited (103)
US 5571551A · Fusi et al. · 1996 [cited by applicant]
US 5639500A · Fusi et al. · 1997 [cited by applicant]
US 6489287B1 · Gauthier et al. · 2002 [cited by applicant]
US 8652533B2 · Hara et al. · 2014 [cited by applicant]
US 9181162B2 · Chen et al. · 2015 [cited by applicant]
US 10105378B2 · Tsai et al. · 2018 [cited by applicant]
US 10265336B2 · Tsai et al. · 2019 [cited by applicant]
US 10927138B2 · Tsai et al. · 2021 [cited by applicant]
US 20070197610A1 · Kennis et al. · 2007 [cited by applicant]
US 20080096959A1 · Hara et al. · 2008 [cited by applicant]
US 20090118202A1 · Thekkumkara · 2009 [cited by applicant]
US 20090170928A1 · Bruno et al. · 2009 [cited by applicant]
US 20110287109A1 · Bagley et al. · 2011 [cited by applicant]
US 20170362394A1 · Chigurupati et al. · 2017 [cited by applicant]
US 20180092935A1 · Tsai et al. · 2018 [cited by applicant]
US 20180133237A1 · Tsai et al. · 2018 [cited by applicant]
US 20190201427A1 · Tsai et al. · 2019 [cited by applicant]
US 20190367549A1 · Tsai et al. · 2019 [cited by applicant]
US 20200390791A1 · Tsai et al. · 2020 [cited by applicant]
US 20210214385A1 · Tsai et al. · 2021 [cited by applicant]
US 20220218730A1 · Tsai et al. · 2022 [cited by applicant]
CN 1398871A · 2003 [cited by applicant]
CN 1450077A · 2003 [cited by applicant]
CN 1454599A · 2003 [cited by applicant]
CN 1560077A · 2005 [cited by applicant]
CN 1568968A · 2005 [cited by applicant]
CN 1602853A · 2005 [cited by applicant]
CN 101618066A · 2010 [cited by applicant]
CN 102127125A · 2011 [cited by applicant]
CN 102180917A · 2011 [cited by applicant]
CN 102250159A · 2011 [cited by applicant]
CN 102743419A · 2012 [cited by applicant]
CN 105592892A · 2016 [cited by applicant]
CN 105687226A · 2016 [cited by applicant]
EP 0413056A1 · 1991 [cited by applicant]
EP 3257513A1 · 2017 [cited by applicant]
JP 2003238495A · 2003 [cited by applicant]
JP 2005538987A · 2005 [cited by applicant]
JP 2012116791A · 2012 [cited by applicant]
JP 2013075849A · 2013 [cited by applicant]
JP 2013249263A · 2013 [cited by applicant]
KR 20090072527A · 2009 [cited by applicant]
KR 20090084159A · 2009 [cited by applicant]
WO 0015044A1 · 2000 [cited by applicant]
WO 2008131047A2 · 2008 [cited by applicant]
WO 2009000864A1 · 2008 [cited by applicant]
WO 2010056413A2 · 2010 [cited by applicant]
WO 2011085454A1 · 2011 [cited by applicant]
WO 2012144754A2 · 2012 [cited by applicant]
WO 2013096182A2 · 2013 [cited by applicant]
WO 2016146026A1 · 2016 [cited by applicant]
WO 2017122495A1 · 2017 [cited by applicant]
WO 2017167168A1 · 2017 [cited by applicant]
WO 2019109300A1 · 2019 [cited by applicant]
WO 2019228408A1 · 2019 [cited by applicant]
WO 2021155864A1 · 2021 [cited by applicant]
(1986) Daurgandhyaham Udvartana. Rasamtnakara-Rasendra. Datto Vallal Borakara, 2nd Ed. Shri Gajanan Book Depot (Pune), 2 pages. [cited by applicant]
(2011) Nuts and Seeds in Health and Disease Prevention, 1st Edition. Preedy, Ed. Academic Press, 14:506. [cited by applicant]
Abdelwahed et al. (2007) “Study of Antimutagenic and Antioxidant Activities of Gallic Acid and 1,2,3,4,6-Pentagalloylglucose from Pistacia Lentiscus Confirmation by Microarray Expression Profiling”, Chemico-Biological I… [cited by applicant]
Ashibe et al. (Nov. 2017) “Non-Enzymatic Oxidation of a Pentagalloylglucose Analogue into Members of the Ellagitannin Family”, Angewandte Chemie International Edition in English, 56(48):15402-15406. [cited by applicant]
Chen et al. (Apr. 7, 2005) “Inhibition of SARS-CoV 3C-Like Protease Activity by Theaflavin-3, 3′-Digallate (TF3)”, Evidence-Based Complementary and Alternative Medicine, 2(2):209-215. [cited by applicant]
Chiou et al. (Jan. 6, 2021) “The Inhibitory Effects of PGG and EGCG Against the SARS-CoV-2 3C-Like Protease”, Biochemical and Biophysical Research Communications, 591:130-136. [cited by applicant]
Crabtree et al. (Dec. 31, 1965) “Gallotannins. Part XI? Synthesis of m-Digallic and m-Trigallic Acids and Their Derivatives”, Journal of the Chemical Society, 6888-6693. [cited by applicant]
Fan et al. (Jul. 2013) “Inhibitory Effects of Tannic Acid on Fatty Acid Synthase and 3T3-L1 Preadipocyte”, Biochimica et Biophysica Acta, 1831(7):1260-1266. [cited by applicant]
Fiuza et al. (May 18, 2004) “Phenolic Acid Derivatives with Potential Anticancer Properties—A Structure-Activity Relationship Study. Part 1: Methyl, Propyl and Octyl Esters of Caffeic and Gallic Acids”, Bioorganic & Med… [cited by applicant]
Goff Donald C, (Jun. 2013) “Future Perspectives on the Treatment of Cognitive Deficits and Negative Symptoms in Schizophrenia”, World Psychiatry, 12(2):99-107. [cited by applicant]
Halkes et al. (2001) “The Use of Tannic Acid in the Local Treatment of Burn Wounds: Intriguing Old and New Perspectives”, Wounds, 13(4):1-19. [cited by applicant]
Hatano et al. (Dec. 31, 1990) “Gallotannins Having a 1, 5-Anhydro-D-Glucitol Core and Some Ellagitannins from Acer Species”, Chemical and Pharmaceutical Bulletin, 38(7):1902-1905. [cited by applicant]
Hu et al. (1992) “Mitogenic Activity of (−)Epigallocatechin Gallate on B-Cells and Investigation of Its Structure-Function Relationship”, International Journal of Immunopharmacology, 14(8):1399-1407. [cited by applicant]
Jeyaseelan et al. (Oct. 2012) “Antibacterial Activity of Sequentially Extracted Organic Solvent Extracts of Fruits, Flowers and Leaves of [cited by applicant]
Karas et al. (2017) “Galloylation of Polyphenols Alters Their Biological Activity”, Food and Chemical Toxicology, 105:223-240. [cited by applicant]
Lavoie et al. (Sep. 9, 2015) “Complete (1)H and (13)C NMR Assignments of a Series of Pergalloylated Tannins”, Magnetic Resonance in Chemistry, 54(2):168-174. [cited by applicant]
Liou et al. (1976) “Optimal Operating Conditions on Batch Extraction”, National Chiao Tung University, 2:83-94. [cited by applicant]
Liu et al. (2018) “In Vivo and In Vitro Anti-Arthritic Effects of Cardenolide-Rich and Caffeoylquinic Acid-Rich Fractions of Periploca Forrestii”, Molecules, 23(8):1988(1-16). [cited by applicant]
Liu et al. (Feb. 2005) “Tannic Acid Stimulates Glucose Transport and Inhibits Adipocyte Differentiation in 3T3-L1 Cells.”, Journal of Nutrition, 135(2):165-171. [cited by applicant]
Ma et al. (2015) “The Hydrolyzable Gallotannin, Penta-o-galloy1-0-d-Glucopyranoside, Inhibits the Formation of Advanced Glycation Endproducts by Protecting Protein Structure”, Molecular BioSystems, 11(5):40 pages. [cited by applicant]
Nakazono et al. (Sep.-Oct. 2010) “Chemiluminescence Enhancement of 1,2-di[3,4,5-tri(3,4,5- Trihydroxybenzoyloxy)Benzoyloxy] Benzene in the Presence of Quaternary Ammonium Ions.”, Luminescence, 25(5):360-363. [cited by applicant]
Nakazono et al. (2002) “Synthesis of Poly (3,4,5-Trihydroxybenzoate Ester) Dendrimers and Their Chemiluminescence”, Tetrahedron Letters, 43(45):8185-8189. [cited by applicant]
Niemetz et al. (Dec. 2000) “Llagitannin Biosynthesis: Oxidation of Pentagalloylglucose to Tellimagrandin Ii by an Enzyme from Tellima Grandiflora Leaves”, Chemical Communications, 11:35-36. [cited by applicant]
Nishizawa et al. (Dec. 31, 1980) “Structure of Gallotannins in Paeoniae Radix”, Chemical & Pharmaceutical Bulletin, 28(9):2850-2852. [cited by applicant]
Nishizawa et al. (1982) “Tannins and Related Compounds. Part 5. Isolation and Characterization of Polygalloylglucoses From Chinese Gallotannin”, Journal of the Chemical Society, Perkin Transactions 1, 0:2963-2968. [cited by applicant]
Ono et al. (Nov. 5, 2004) “Anti-amyloidogenic Activity of Tannic Acid and Its Activity to Destabilize Alzheimer's Betaamyloid Fibrils in Vitro”, Biochimica et Biophysica Acta, 1690(3):193-202. [cited by applicant]
Park et al. (Apr. 22, 2013) “Dieckol, a SARS-CoV 3CL(pro) Inhibitor, Isolated From the Edible Brown Algae [cited by applicant]
Qiao et al. (Jul. 2011) “Research Progress in Galla Chinensis and Gallic Tannins”, Science and Technology of Food Industry, 31:458-462. [cited by applicant]
Ren et al. (May 2006) “Synthesis and Structure-Activity Relationship Study of Antidiabetic Penta-o-Galloyl-Dglucopyranose and its Analogues.”, Journal of Medicinal Chemistry, 49(9):2829-2837. [cited by applicant]
Sancheti et al. (Apr. 2010) “1,2,3,4,6-Penta-0-Galloy1-0-D-Glucose: A Cholinesterase Inhibitor from Terminalia Chebula”, South African Journal of Botany, 76(2):285-288. [cited by applicant]
Sekowski et al. (Apr. 10, 2017) “Interaction of α-Synuclein with Rhus typhina Tannin—Implication for Parkinson's Disease”, Colloids and Surfaces B: Biointerfaces, 155:159-165. [cited by applicant]
Sieniawska et al. (Nov. 2015) “Activities of Tannins—From In Vitro Studies to Clinical Trials”, Natural Product Communications, 10(11):1877-1884. [cited by applicant]
Smith et al. (2010) “The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors”, The Open Medicinal Chemistry Journal, 4:3-9. [cited by applicant]
Sylla et al. (2015) “Gallotannins and Tannic Acid: First Chemical Syntheses and In Vitro Inhibitory Activity on Alzheimer's Amyloid 13-Peptide Aggregation”, Angewandte Chemie, 127(28):8335-8339. [cited by applicant]
Sylla et al. (May 26, 2015) “Gallotannins and Tannic Acid: First Chemical Syntheses and In Vitro Inhibitory Activity on Alzheimer's Amyloid B-Peptide Aggregation”, Angewandte Chemie, 54(28):8217-8221. [cited by applicant]
Theisen et al. (Jan. 31, 2014) “Tannins from Hamamelis Virginiana Bark Extract: Characterization and Improvement of the Antiviral Efficacy Against Influenza a Virus and Human Papillomavirus”, PLoS One, 9(1):e88062 (1-14… [cited by applicant]
Tian et al. (Mar. 2009) “Antioxidant and Antimicrobial Activities of Consecutive Extracts from Galla Chinensis: The Polarity Affects the Bioactivities”, Food Chemistry, 113(1):173- 179. [cited by applicant]
Toda et al. (2001) “Inhibitory Effects of Ellagi- and Gallotannins on Rat Intestinal Alpha- glucosidase Complexes”, Bioscience, Biotechnology, and Biochemistry, 65(3):542-547. [cited by applicant]
Venter et al. (Sep. 2019) “Comprehensive Analysis of Tara Tannins by Reversed-Phase and Hydrophilic Interaction Chromatography Coupled to Ion Mobility and High-Resolution Mass Spectrometry”, Analytical and Bioanalytical… [cited by applicant]
Mswanatha et al. (2013) “Anticonvulsant Activity of 1,2,3,4,6-Penta-o-Galloy1-0-d-Glucopyranose Isolated from Leaves of Mangifera Indica.”, Naunyn-Schmiedeberg's Archives of Pharmacology, 386(7):599-604. [cited by applicant]
Wu et al. (Mar. 2015) “Preparation of Gallnut Tannins Liposome and Its Quality Evaluation”, Science and Technology of Food Industry, 36(3):74-77. [cited by applicant]
Delahaye et al. (1983) “Trigallic Acid or Trimeric Gallic Acid”, Belgian Chemical Companies, 92(5):469-472. [cited by applicant]
Lee et al. (2012) “Synthesis of Poly (3,4,5-trihydroxybenzoate amide) and Poly (3,4,5-trihydroxybenzoate ester) Dendrimers from Polyphenols and their Chemiluminescence”, Korean Chemical Society, 33(6):2051-2054. [cited by applicant]
Lin et al. (Dec. 23, 2002) “Polyphenolic Compounds from the Leaves of Koelreuteria paniculata Laxm”, Journal of Asian Natural Products Research, 4(4):287-295. [cited by applicant]
Richards et al. (Oct. 1987) “Study of Reaction Rates of the Antioxidants Gallic Acid, Bht and Bha Using the Technique of Pulse Radiolysis”, International Journal of Food Science and Technology, 22(5):501-508. [cited by applicant]
Wuts et al. (Dec. 13, 2006) “Greene's Protective Groups in Organic Synthesis”, J. Am. Chem. Soc., 4th Edition, pp. 1-7 and 306-310. [cited by applicant]
Yi et al. (Oct. 1, 2004) “Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus Into Host Cells”, Journal of Virology, The American Society for Microbiology, US, DOI:10.1128/JVI, 78(20):113… [cited by applicant]